JP7359782B2 - ブルトン型チロシンキナーゼに対する阻害剤 - Google Patents

ブルトン型チロシンキナーゼに対する阻害剤 Download PDF

Info

Publication number
JP7359782B2
JP7359782B2 JP2020564219A JP2020564219A JP7359782B2 JP 7359782 B2 JP7359782 B2 JP 7359782B2 JP 2020564219 A JP2020564219 A JP 2020564219A JP 2020564219 A JP2020564219 A JP 2020564219A JP 7359782 B2 JP7359782 B2 JP 7359782B2
Authority
JP
Japan
Prior art keywords
methyl
alkyl
membered monocyclic
tert
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523206A (ja
JP2021523206A5 (enExample
Inventor
ホプキンス,ブライアン・ティー
マー,ビン
プリンス,ロビン
マルクス,アイザック
シュルツ,ユルゲン
ネバライネン,マルタ
デチャンツライター,マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of JP2021523206A publication Critical patent/JP2021523206A/ja
Publication of JP2021523206A5 publication Critical patent/JP2021523206A5/ja
Application granted granted Critical
Publication of JP7359782B2 publication Critical patent/JP7359782B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2020564219A 2018-05-14 2019-05-13 ブルトン型チロシンキナーゼに対する阻害剤 Active JP7359782B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862671053P 2018-05-14 2018-05-14
US62/671,053 2018-05-14
PCT/US2019/032018 WO2019222101A1 (en) 2018-05-14 2019-05-13 Inhibiting agents for bruton's tyrosine kinase

Publications (3)

Publication Number Publication Date
JP2021523206A JP2021523206A (ja) 2021-09-02
JP2021523206A5 JP2021523206A5 (enExample) 2022-05-18
JP7359782B2 true JP7359782B2 (ja) 2023-10-11

Family

ID=67002348

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564219A Active JP7359782B2 (ja) 2018-05-14 2019-05-13 ブルトン型チロシンキナーゼに対する阻害剤

Country Status (9)

Country Link
US (1) US10899753B2 (enExample)
EP (1) EP3793994B1 (enExample)
JP (1) JP7359782B2 (enExample)
AR (1) AR115085A1 (enExample)
ES (1) ES2968222T3 (enExample)
MA (1) MA52629A (enExample)
TW (1) TW202016097A (enExample)
UY (1) UY38233A (enExample)
WO (1) WO2019222101A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11820760B2 (en) * 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
EP4081514A1 (en) * 2019-12-23 2022-11-02 Biogen MA Inc. Btk inhibitors
CN112062691B (zh) * 2020-06-18 2022-12-09 中国农业科学院油料作物研究所 一种柠檬醛苯丁酸肟酯类化合物及其合成方法和应用
EP4313023A1 (en) 2021-04-02 2024-02-07 Biogen MA Inc. Combination treatment methods of multiple sclerosis
KR20240128831A (ko) 2021-12-30 2024-08-27 베이진 스위찰랜드 게엠베하 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133367A1 (ja) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase
JP2016539996A (ja) 2013-12-11 2016-12-22 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
EP3444251B1 (en) 2013-12-11 2023-06-07 Biogen MA Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013133367A1 (ja) 2012-03-09 2013-09-12 カルナバイオサイエンス株式会社 新規トリアジン誘導体
JP2016539996A (ja) 2013-12-11 2016-12-22 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 腫瘍学、神経学及び免疫学におけるヒト疾患の治療に有用なビアリール化合物
WO2016201280A1 (en) 2015-06-10 2016-12-15 Biogen Ma Inc. Forms and compositions of biaryl inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
ES2968222T3 (es) 2024-05-08
AR115085A1 (es) 2020-11-25
MA52629A (fr) 2021-03-24
EP3793994B1 (en) 2023-08-23
TW202016097A (zh) 2020-05-01
WO2019222101A1 (en) 2019-11-21
JP2021523206A (ja) 2021-09-02
UY38233A (es) 2019-12-31
US10899753B2 (en) 2021-01-26
US20190382394A1 (en) 2019-12-19
EP3793994A1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
JP7359782B2 (ja) ブルトン型チロシンキナーゼに対する阻害剤
JP7778206B2 (ja) ブルトン型チロシンキナーゼの阻害剤としてのベンゾアゼピン類似体
JP7758664B2 (ja) ブルトン型チロシンキナーゼに対する阻害剤としての縮合型二複素環
JP2018502159A (ja) Btk阻害剤
JP7597781B2 (ja) 化学化合物
JP7779900B2 (ja) Btk阻害剤
JP2025094159A (ja) ブルトン型チロシンキナーゼの阻害剤
JP2024544529A (ja) Btk阻害剤
JP7758665B2 (ja) Btk阻害剤としての縮合ピリダジンまたはピリミジン
EP3853225B1 (en) N-(5-(3-(1-((thiazol-2-yl)amino)-1-oxopropan-2-yl)phenyl)pyridin-2-yl)acrylamide derivatives as cdk7 inhibitors for the treatment of cancer
EP4081514A1 (en) Btk inhibitors
HK40049019A (en) Inhibiting agents for bruton's tyrosine kinase
HK40049019B (en) Inhibiting agents for bruton's tyrosine kinase
TWI921490B (zh) 哺乳動物slc6a19功能之小分子抑制劑
CN114450005A (zh) 用于治疗神经障碍的化合物
HK40102628A (zh) Btk抑制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220510

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230815

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230904

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230928

R150 Certificate of patent or registration of utility model

Ref document number: 7359782

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150